Print

ACADIA Pharmaceuticals, Inc. (ACAD) Announces Extension of Drug Discovery Collaboration with Allergan Inc. (AGN)  
3/5/2012 7:36:57 AM

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is currently focused on the discovery of new therapeutics for glaucoma and other ophthalmic indications and was originally established in March 2003. The research term of this collaboration has now been extended by the parties for an additional year through March 2013. ACADIA also has two other collaboration agreements with Allergan, which have led to clinical programs in the areas of chronic pain and glaucoma.
//-->